卡马替尼治疗MET外显子澳门葡京网址14突变或MET扩增的非小细胞
抢庄牛牛网汇集了世界上最顶级的彩票、体育、真人视讯、游戏等娱乐节目,【415161.com】供广大市民创造财富与娱乐并齐抢庄牛牛娱乐网站。
王者荣耀 迷你世界
MESSAGE球球大作战
热线电话:
4008-888-8899
首页
王者荣耀
绝地求生
QQ飞车
红色警戒
第五人格
皇室战争
球球大作战
迷你世界
绝地求生

迷你世界

当前位置:主页 > 绝地求生 > 迷你世界 >

卡马替尼治疗MET外显子澳门葡京网址14突变或MET扩增的非小细胞

发布时间:2020-09-06

Sylvie Le Mouhaer, phase 2 study evaluating capmatinib in patients with MET-dysregulated advanced NSCLC. Patients were assigned to cohorts on the basis of previous lines of therapy and MET status (MET exon 14 skipping mutation or MET amplification according to gene copy number in tumor tissue). Patients received capmatinib (400-mg tablet) twice daily. The primary end point was overall response (complete or partial response), Ji-Youn Han, M.D.,治疗效果有限, M.D.。

最新IF:70.67 官方网址: 投稿链接: 。

, particularly in those not treated previously. The efficacy in MET-amplified advanced NSCLC was higher in tumors with a high gene copy number than in those with a low gene copy number. Low-grade peripheral edema and nausea were the main toxic effects. DOI: 10.1056/NEJMoa2002787 Source: https://www.nejm.org/doi/full/10.1056/NEJMoa2002787 期刊信息